This program project grant has as its focus clinical-laboratory investigations of new chemotherapeutic approaches for the treatment of human malignacies. New concepts, drugs or therapeutic approaches that arise from laboratory studies, are explored, when approprite in patients with malignant disease. The emphasis of clinical studies are Phase I and II trials, in association with community physicians (CCOP's), and by two larger cooperative groups (Gastrointestinal Tumor Study Group and the Eastern Cooperative Oncology Group). Specific projects include development of second generation antifolates (Project 1), inhibitors of calmodulin as antitumor agents (Project 2), chemotherapy-endocrine interactions (Projects 3), new approaches to regional therapy (Projects 4 and 5), studies of differentiation of squamous cell carcinoma (Project 6), the use of monoclonal antibodies in the diagnosis and possible treatment of acute myeloid leukemia (Project 8) and in melanoma (Project 7), development of sensitive immunoassays for early diagnosis of fungal infections in immunocompromised patients (Project 9), and the use of drug resistant genes to confer resistance of bone marrow stem cells to methotrexate. These projects are closely integrated with the Phase I-II clinical studies proposed in patients with acute leukemia, lymphoma, head and neck cancer, gastrointestinal cancer and in melanoma (Project 11). Integration and collaborations among the projects is achieved by the use fo common technologies (e.g., use of monoclonal antibodies in Projects 7, 8, 9, 10), collaboration among investigators with expertise in certain areas (i.e., projects 1, 3, 4, 5, 6, 10), and by linkage of laboratory programs to clinical investigations; i.e., Project 1 to trials in leukemia, head and neck cancer, and in colorectal cancer; Project 3 with future trials in breast cancer, Project 4 with trials in ovarian cancer, Project 6 with future trials in head and neck cancer. Project 8 with acute leukemia, Project 7 with melanoma trials, Project 9 with acute leukemia trials, and Project 10 with future trials in head and neck cancer and lymphoma. These projects are dependent upon Core functions that provide administrative support and data management and biostatistical support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA008341-20
Application #
3092518
Study Section
(SRC)
Project Start
1976-01-01
Project End
1989-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
20
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Yale University
Department
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
Yang, J M; Sullivan, G F; Hait, W N (1997) Regulation of the function of P-glycoprotein by epidermal growth factor through phospholipase C. Biochem Pharmacol 53:1597-604
Yang, J M; Chin, K V; Hait, W N (1996) Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells. Cancer Res 56:3490-4
Buzaid, A C; Pizzorno, G; Marsh, J C et al. (1995) Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study. Cancer Chemother Pharmacol 36:373-8
Yang, J M; Chin, K V; Hait, W N (1995) Involvement of phospholipase C in heat-shock-induced phosphorylation of P-glycoprotein in multidrug resistant human breast cancer cells. Biochem Biophys Res Commun 210:21-30
Marsh, J C; Durivage, H J; Davis, C et al. (1992) Phase II study of pulse 5-fluoro-2'-deoxyuridine and leucovorin in advanced colorectal cancer patients previously treated with chemotherapy. Am J Clin Oncol 15:115-8
Aftab, D T; Ballas, L M; Loomis, C R et al. (1991) Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C. Mol Pharmacol 40:798-805
Murren, J R; Ganpule, S; Sarris, A et al. (1991) A phase II trial of cyclosporin A in the treatment of refractory metastatic colorectal cancer. Am J Clin Oncol 14:208-10
Murren, J R; Buzaid, A C; Hait, W N (1991) Critical analysis of neoadjuvant therapy for Stage IIIa non-small cell lung cancer [corrected] Am Rev Respir Dis 143:889-94
Hait, W N; Byrne, T N; Piepmeier, J et al. (1990) The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas. Cancer Res 50:6636-40
Kacinski, B M; Chambers, S K; Stanley, E R et al. (1990) The cytokine CSF-1 (M-CSF) expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients. Int J Radiat Oncol Biol Phys 19:619-26

Showing the most recent 10 out of 11 publications